New combo attack on myeloma: antibody first, then CAR-T
NCT ID NCT07185477
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests whether giving a bispecific antibody (QLS32015) before CAR-T cell therapy can improve outcomes for 20 adults with relapsed/refractory multiple myeloma. The study measures how many patients respond and tracks side effects. It is a single-arm, open-label design, so results will be compared to historical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLS32015 (a bispecific antibody targeting GPRC5D and CD3) and BCMA CAR-T cells
What this could lead to
If successful, this approach could improve treatment responses for patients with hard-to-treat multiple myeloma by using a two-step immune therapy.
What could go wrong
This is a very early, small trial (20 people) with no control group. The combination may cause serious side effects or not work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.